28.57
12.08%
+3.08
After Hours:
28.70
0.13
+0.46%
PTC Therapeutics Inc stock is currently priced at $28.57, with a 24-hour trading volume of 1.52M.
It has seen a +12.08% increased in the last 24 hours and a +2.18% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $25.05 pivot point. If it approaches the $27.75 resistance level, significant changes may occur.
Previous Close:
$25.49
Open:
$27
24h Volume:
1.52M
Market Cap:
$2.19B
Revenue:
$937.82M
Net Income/Loss:
$-626.60M
P/E Ratio:
-3.3029
EPS:
-8.65
Net Cash Flow:
$-279.04M
1W Performance:
+12.84%
1M Performance:
+2.18%
6M Performance:
+19.29%
1Y Performance:
-45.31%
PTC Therapeutics Inc Stock (PTCT) Company Profile
Name
PTC Therapeutics Inc
Sector
Industry
Phone
908-222-7000
Address
100 Corporate Court, South Plainfield, NJ
PTC Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
Oct-06-23 | Downgrade | Truist | Buy → Hold |
Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
Mar-17-23 | Initiated | SVB Securities | Market Perform |
Dec-14-22 | Initiated | Goldman | Sell |
Sep-12-22 | Initiated | Jefferies | Buy |
Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
Sep-01-22 | Initiated | Citigroup | Buy |
Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
Apr-26-21 | Resumed | Credit Suisse | Neutral |
Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
Oct-28-20 | Initiated | UBS | Neutral |
Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
Aug-25-20 | Initiated | Raymond James | Outperform |
Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-12-19 | Initiated | SunTrust | Buy |
May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Apr-11-19 | Initiated | Bernstein | Outperform |
Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
Jul-19-18 | Initiated | Credit Suisse | Outperform |
Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
PTC Therapeutics Inc Stock (PTCT) Latest News
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Zacks Investment Research
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
Zacks Investment Research
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Benzinga
Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings
Zacks Investment Research
PTC Therapeutics Inc Stock (PTCT) Financials Data
PTC Therapeutics Inc (PTCT) Revenue 2024
PTCT reported a revenue (TTM) of $937.82 million for the quarter ending December 31, 2023, a +34.20% rise year-over-year.
PTC Therapeutics Inc (PTCT) Net Income 2024
PTCT net income (TTM) was -$626.60 million for the quarter ending December 31, 2023, a -12.09% decrease year-over-year.
PTC Therapeutics Inc (PTCT) Cash Flow 2024
PTCT recorded a free cash flow (TTM) of -$279.04 million for the quarter ending December 31, 2023, a +45.19% increase year-over-year.
PTC Therapeutics Inc (PTCT) Earnings per Share 2024
PTCT earnings per share (TTM) was -$8.36 for the quarter ending December 31, 2023, a -7.32% decline year-over-year.
PTC Therapeutics Inc Stock (PTCT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Apr 19 '24 |
Sale |
24.89 |
3,361 |
83,669 |
225,807 |
Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Apr 17 '24 |
Sale |
25.14 |
1,307 |
32,851 |
229,168 |
Pauwels Eric | CHIEF EXECUTIVE OFFICER |
Apr 17 '24 |
Sale |
25.14 |
787 |
19,781 |
67,694 |
Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Apr 02 '24 |
Sale |
28.37 |
526 |
14,923 |
59,988 |
Boulding Mark Elliott | EXEC. VP AND CLO |
Jan 30 '24 |
Sale |
27.25 |
794 |
21,637 |
71,189 |
Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 30 '24 |
Sale |
27.25 |
618 |
16,841 |
61,202 |
Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 30 '24 |
Sale |
27.25 |
366 |
9,974 |
44,181 |
Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER |
Jan 30 '24 |
Sale |
27.25 |
318 |
8,666 |
35,528 |
Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 30 '24 |
Sale |
27.25 |
28 |
763 |
3,706 |
Jacobson Allan Steven | Director |
Jan 22 '24 |
Option Exercise |
27.05 |
10,000 |
270,500 |
22,348 |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and research collaboration with CHDI Foundation, Inc. to discover and develop small-molecule therapeutics for Huntington's disease. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Cap:
|
Volume (24h):